Axim Biotechnologies Inc Revenue Growth Rates (AXIM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Axim Biotechnologies Inc   (AXIM)
 

AXIM's Revenue Growth by Quarter and Year

Axim Biotechnologies Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AXIM Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.02
1st Quarter March 0.05
FY 0.07

AXIMs Annual Revenue
Axim Biotechnologies Inc 's Revenue in the fiscal year 2023 $ 0.04 millions
Axim Biotechnologies Inc 's Revenue in the fiscal year 2022 $ 0.01 millions
Axim Biotechnologies Inc 's Revenue in the fiscal year 2021 $ 0.06 millions
Axim Biotechnologies Inc 's Revenue in the fiscal year 2020 $ 0.00 millions
Axim Biotechnologies Inc 's Revenue in the fiscal year 2019 $ 0.80 millions




AXIM Revenue second quarter 2024 Y/Y Growth Comment
Axim Biotechnologies Inc reported Revenue surge of 74.79% year on year in the second quarter 2024, to $ 0.02 millions, this is lower than Axim Biotechnologies Inc 's recent average Revenue surge of 380.26%.

Looking into second quarter 2024 results within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Revenue growth. While Axim Biotechnologies Inc ' s Revenue jump of 74.79% ranks overall at the positon no. 211 in the second quarter 2024.


AXIM Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 0 % - -
3rd Quarter September - - - -
2nd Quarter June 74.79 % - - -
1st Quarter March 400 % - - 200 %
FY   - 300 % -80 % -

Financial Statements
Axim Biotechnologies Inc 's second quarter 2024 Revenue $ 0.02 millions AXIM's Income Statement
Axim Biotechnologies Inc 's second quarter 2023 Revenue $ 0.01 millions Quarterly AXIM's Income Statement


AXIM Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 0 % - -
3rd Quarter September - 0 % - 0 %
2nd Quarter June -65.04 % 0 % - -66.67 %
1st Quarter March 400 % 0 % - -
FY (Year on Year)   - 300 % -80 % -


Back to AXIM Growth rate Comparisons >> Back to AXIM Growth rate Comparisons >>


Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #88
Overall #211

Revenue Y/Y Growth Statistics
High Average Low
6375.13 % 380.26 % -100 %
(Sep 30 2019)   (Jun 30 2022)
Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #88
Overall #211
Revenue Y/Y Growth Statistics
High Average Low
6375.13 % 380.26 % -100 %
(Sep 30 2019)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Axim Biotechnologies Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2582.65 % 118.05 % -100 %
(Dec 31 2018)  


AXIM's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2024 Axim Biotechnologies Inc disclosed fall in Revenue from the first quarter by -65.04% to $ 0.02 millions, from $ 0.05 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 224 other companies have achieved higher Revenue quarter on quarter growth. While Axim Biotechnologies Inc 's Revenue growth quarter on quarter, overall rank is 3896.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #225
Healthcare Sector #602
Overall #3896
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #225
Healthcare Sector #602
Overall #3896
Revenue Q/Q Growth Statistics
High Average Low
2582.65 % 118.05 % -100 %
(Dec 31 2018)  


AXIM's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2024 Axim Biotechnologies Inc disclosed fall in Revenue from the first quarter by -65.04% to $ 0.02 millions, from $ 0.05 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 224 other companies have achieved higher Revenue quarter on quarter growth. While Axim Biotechnologies Inc 's Revenue growth quarter on quarter, overall rank is 3896.


Axim Biotechnologies Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Revenue 12 Months Ending $ 0.09 $ 0.09 $ 0.04 $ 0.03 $ 0.03
Y / Y Revenue Growth (TTM) 253.61 % - - - -
Year on Year Revenue Growth Overall Ranking # 54 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 8.87 % 115.34 % 14.65 % 31.55 % -
Seq. Revenue Growth (TTM) Overall Ranking # 413 # 269 # 419 # 481 # 0


Cumulative Revenue growth Comment
Although Axim Biotechnologies Inc 's Annual Revenue growth year on year were below company's average 260.06% , Revenue announced in the Jun 30 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 253.61% year on year, from % in Mar 31 2024.

Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 54.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 69
Healthcare Sector # 20
Overall # 54

Revenue TTM Y/Y Growth Statistics
High Average Low
1442.14 %
 260.06 %
-40.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 69
Sector # 130
S&P 500 # 413
Cumulative Revenue growth Comment
Although Axim Biotechnologies Inc 's Annual Revenue growth year on year were below company's average 260.06% , Revenue announced in the Jun 30 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 253.61% year on year, from % in Mar 31 2024.

Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 54.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 69
Healthcare Sector # 20
Overall # 54

Revenue TTM Y/Y Growth Statistics
High Average Low
1442.14 %
260.06 %
-40.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 69
Sector # 130
S&P 500 # 413




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AXIM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Evoke Pharma Inc 125.51%$ 125.512 millions
Ovid Therapeutics Inc 125.33%$ 125.333 millions
Fennec Pharmaceuticals Inc 118.41%$ 118.406 millions
Transmedics Group Inc 117.87%$ 117.869 millions
Orgenesis Inc 117.70%$ 117.699 millions
Globus Medical Inc 115.93%$ 115.932 millions
Longeveron Inc 115.67%$ 115.668 millions
Elite Pharmaceuticals Inc 111.13%$ 111.127 millions
Apellis Pharmaceuticals Inc 110.26%$ 110.263 millions
60 Degrees Pharmaceuticals Inc 109.92%$ 109.924 millions
Vivos Inc107.69%$ 107.692 millions
Mirum Pharmaceuticals Inc 107.68%$ 107.683 millions
Alnylam Pharmaceuticals Inc 107.00%$ 107.001 millions
Calliditas Therapeutics Ab104.51%$ 104.505 millions
Sensus Healthcare Inc 104.09%$ 104.087 millions
Tff Pharmaceuticals Inc95.06%$ 95.056 millions
Cue Biopharma Inc 92.33%$ 92.330 millions
Arcellx Inc 91.47%$ 91.470 millions
Pmgc Holdings Inc 91.31%$ 91.311 millions
Curevac N v 88.34%$ 88.337 millions
Regen Biopharma Inc 86.68%$ 86.678 millions
Axsome Therapeutics Inc 86.65%$ 86.651 millions
Universal Biosensors Inc 86.62%$ 86.623 millions
Volitionrx Limited82.98%$ 82.977 millions
Innovative Eyewear Inc 81.65%$ 81.654 millions
Adma Biologics Inc 78.34%$ 78.343 millions
Metagenomi Therapeutics Inc 76.48%$ 76.484 millions
Ispecimen inc 76.21%$ 76.211 millions
Axim Biotechnologies Inc 76.04%$ 76.040 millions
Rosecliff Acquisition Corp I75.91%$ 75.912 millions


About Axim Biotechnologies Inc Revenue Growth Rates (AXIM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Axim Biotechnologies Inc (CIK 1514946).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001096906-24-001772
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Axim Biotechnologies Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.